사이코바이오틱 원료 시장 : 시장 기회, 성장 요인, 업계 동향 분석 및 예측(2025-2034년)

The Global Psychobiotic Ingredients Market was valued at USD 305.1 million in 2024 and is estimated to grow at a CAGR of 11.4% to reach USD 936.8 million by 2034.

Psychobiotic ingredients consist of targeted probiotic strains that support emotional well-being by influencing pathways within the gut-brain connection. These microorganisms come from bacterial groups known for their ability to affect neurological activity, neurotransmitter signaling, and overall psychological balance. They operate through diverse biological actions, including the formation of neuroactive molecules, regulation of the HPA axis, moderation of inflammatory responses, strengthening of the intestinal barrier, and stimulation of neural communication between the gut and the brain. Their components interact with digestive and immune cells to send signals that may influence mood and cognitive processes. Research findings have shown measurable improvements in stress markers, hormonal balance, anxiety indicators, and cognitive performance when individuals use these ingredients consistently. As interest in the microbiome and mental wellness continues to rise, psychobiotics are transitioning from early scientific exploration to established commercial solutions supported by strain-specific clinical evidence. Greater public understanding of mental health, combined with growing interest in natural and science-backed wellness products, is driving broader market acceptance.

The bifidobacterium species segment held 40% share in 2024 and is expected to grow at a CAGR of 15.1% through 2034. These species lead the market due to their well-documented effects on gut-brain communication, supported by strong research that highlights their ability to influence neurotransmitter pathways, stress response systems, and inflammatory markers.

The stress management segment accounted for 31% share in 2024 and is projected to grow at a CAGR of 10% through 2034. This segment continues to expand because consumers seek reliable solutions supported by scientific evidence showing reductions in stress-related biomarkers and improved overall resilience.

North America Psychobiotic Ingredients Market held a 10.8% share in 2024 and continues to show steady advancement. The region benefits from an established scientific community focused on microbiome research, growing awareness of the gut-brain connection, and a strong supplement industry. Awareness initiatives, workplace wellness programs, and demand for clinically supported natural products further reinforce regional growth.

Major companies active in the Psychobiotic Ingredients Market include FrieslandCampina Ingredients, Seed Health, DSM-Firmenich, ADM, Lallemand Health Solutions, Winclove Probiotics B.V., Unique Biotech Limited, Novonesis (Chr. Hansen Holding A/S), Probi AB, Kerry Group plc, BioGaia AB, Bened Biomedical Co., Ltd., AB-Biotics (KANEKA subsidiary), and Gnosis by Lesaffre. Companies in the Psychobiotic Ingredients Market use several strategic approaches to reinforce their competitive standing. Many invest in advanced strain development and clinical research to build strong scientific validation for mental wellness benefits. Partnerships with supplement brands, food manufacturers, and research institutions help expand commercial reach and accelerate innovation. Firms also emphasize regulatory alignment to support claims related to stress, mood, and cognitive health. Product diversification, including formulations tailored for specific consumer groups, strengthens portfolio appeal.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Bacterial strain type
  • 2.2.3 Application
  • 2.2.4 Region
• 2.3 TAM Analysis, 2025-2034
• 2.4 CXO perspectives: Strategic imperatives
  • 2.4.1 Executive decision points
  • 2.4.2 Critical success factors
• 2.5 Future Outlook and Strategic Recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Profit margin
  • 3.1.3 Value addition at each stage
  • 3.1.4 Factor affecting the value chain
  • 3.1.5 Disruptions
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
  • 3.2.2 Industry pitfalls and challenges
  • 3.2.3 Market opportunities
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East & Africa
• 3.5 Porter's analysis
• 3.6 PESTEL analysis
• 3.7 Price trends
  • 3.7.1 By region
  • 3.7.2 By bacterial strain type
• 3.8 Future market trends
• 3.9 Technology and Innovation landscape
  • 3.9.1 Current technological trends
  • 3.9.2 Emerging technologies
• 3.10 Patent Landscape
• 3.11 Trade statistics (HS code) ( Note: the trade statistics will be provided for key countries only)
  • 3.11.1 Major importing countries
  • 3.11.2 Major exporting countries
• 3.12 Sustainability and environmental aspects
  • 3.12.1 Sustainable practices
  • 3.12.2 Waste reduction strategies
  • 3.12.3 Energy efficiency in production
  • 3.12.4 Eco-friendly initiatives
• 3.13 Carbon footprint consideration

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 By region
    • 4.2.1.1 North America
    • 4.2.1.2 Europe
    • 4.2.1.3 Asia Pacific
    • 4.2.1.4 LATAM
    • 4.2.1.5 MEA
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New Product Launches
  • 4.6.4 Expansion Plans

Chapter 5 Market Estimates and Forecast, By Bacterial Strain Type, 2021-2034 (USD Billion) (Kilo Tons)

• 5.1 Key trends
• 5.2 Lactobacillus species
  • 5.2.1 L. plantarum
  • 5.2.2 L. rhamnosus
  • 5.2.3 L. helveticus
  • 5.2.4 L. acidophilus
  • 5.2.5 L. casei
  • 5.2.6 L. reuteri
• 5.3 Bifidobacterium species
  • 5.3.1 B. breve
  • 5.3.2 B. longum
  • 5.3.3 B. infantis
  • 5.3.4 B. lactis
  • 5.3.5 B. bifidum
  • 5.3.6 B. animalis
• 5.4 Bacillus species
  • 5.4.1 B. coagulans
  • 5.4.2 B. subtilis
• 5.5 Other beneficial species

Chapter 6 Market Estimates and Forecast, By Application, 2021-2034 (USD Billion) (Kilo Tons)

• 6.1 Key trends
• 6.2 Stress management
  • 6.2.1 Corporate users
  • 6.2.2 Students
  • 6.2.3 Healthcare workers
• 6.3 Anxiety reduction
  • 6.3.1 Generalized anxiety applications
  • 6.3.2 Social anxiety applications
• 6.4 Depression treatment
  • 6.4.1 Mild-to-moderate depression
  • 6.4.2 Adjunct therapy to antidepressants
• 6.5 Cognitive function enhancement
  • 6.5.1 Memory enhancement
  • 6.5.2 Learning improvement
  • 6.5.3 Executive function support
  • 6.5.4 Aging & dementia prevention
• 6.6 Mood & well-being enhancement
  • 6.6.1 General wellness
  • 6.6.2 Clinical mood applications
• 6.7 Neurological & behavioral disorders
  • 6.7.1 Autism spectrum disorder (ASD)
  • 6.7.2 Attention deficit hyperactivity disorder (ADHD)
  • 6.7.3 Other neurodevelopmental conditions

Chapter 7 Market Estimates and Forecast, By Region, 2021-2034 (USD Billion) (Kilo Tons)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 India
  • 7.4.3 Japan
  • 7.4.4 Australia
  • 7.4.5 South Korea
  • 7.4.6 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
  • 7.5.4 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 Saudi Arabia
  • 7.6.2 South Africa
  • 7.6.3 UAE
  • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

• 8.1 Novonesis (Chr. Hansen Holding A/S)
• 8.2 Bened Biomedical Co., Ltd.
• 8.3 Lallemand Health Solutions
• 8.4 Probi AB
• 8.5 ADM (Archer Daniels Midland)
• 8.6 AB-Biotics (KANEKA subsidiary)
• 8.7 Seed Health
• 8.8 BioGaia AB
• 8.9 Kerry Group plc
• 8.10 FrieslandCampina Ingredients
• 8.11 Gnosis by Lesaffre
• 8.12 Winclove Probiotics B.V.
• 8.13 DSM-Firmenich
• 8.14 Unique Biotech Limited